DEDHAM, Mass.–(BUSINESS WIRE)–DoseSpot, a software-as-a-service (SaaS) platform that enables clinicians to electronically write and transmit prescriptions to pharmacies, has acquired the TreatRx segment of Bravado Health to strengthen and expand DoseSpot’s solution set for healthcare providers and help advance its position in the ePrescribing software integration market.
The acquisition follows a strategic investment in January 2022 led by PSG, a leading growth equity firm partnering with software and technology-enabled services companies to help accelerate their growth. The company remains committed to innovation, and with the addition of TreatRx, DoseSpot should be well positioned to continue executing on its growth strategy, positively impacting patient outcomes and reducing overall healthcare costs across the US.
DoseSpot will integrate Bravado Health’s powerful ePrescribing solution into its existing suite of technology, giving healthcare providers an increasingly comprehensive range of solutions to streamline their prescription workflows. Bravado Health’s existing ePrescribing customers will be supported throughout the transition, with no disruption to service, and will benefit from the added resources and capabilities of DoseSpot.
“We’re thrilled to welcome TreatRx to the DoseSpot community,” said Josh Weiner, CEO of DoseSpot. “This acquisition represents a significant milestone for us as we continue to invest in and expand our ePrescribing platform. By incorporating Bravado Health’s ePrescribing technology and expertise, we can offer even more value to our current and future customers, helping them to practice safe prescribing, increase practice efficiency, and stay compliant with state and federal mandates.”
“This acquisition is an exciting opportunity for DoseSpot and Bravado Health, and we are very much looking forward to working closely with the customer-centric DoseSpot team for the most seamless transition possible for the clients,” said Dana Etheredge, Director of Client Success at Bravado Health. “We know these clients are in the best of hands for their ePrescribing needs.”
“Together, TreatRx and DoseSpot will offer an enhanced, comprehensive solution to healthcare providers that will help them better serve patient needs,” added Bill Skarinka, Managing Director at PSG. “We look forward to supporting the full integration of these solutions and are excited about the opportunity to further advance DoseSpot’s position in the market.”
DoseSpot provides ePrescription software enabling clinicians to write and transmit prescriptions to pharmacies electronically. The solution is Surescripts certified and eases the administrative burden of the prescription life cycle by integrating with EMRs/EHRs and other practice management software. Clinicians can prescribe medication without leaving their core workflows and remain compliant with state-specific and federal regulations for prescribing medication and controlled substances. Founded in 2009 and based in Dedham, MA, DoseSpot serves more than 300 healthcare clients – reaching over 200,000 healthcare professionals – from digital/telehealth providers and hospice pharmacies to dental services organizations and EMR/EHR and practice management software companies. For more information about DoseSpot’s ePrescribing solutions and services, visit www.dosespot.com.
TreatRx, LLC has the award-winning e-prescribing platform, Treat 4. Treat allows for providers’ workflow to be streamlined and made more convenient, working in real-time without requiring an EHR with either its stand-alone web offering or an integrated API connection.
PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 120 companies and facilitated over 430 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Paris, Madrid and Tel-Aviv. To learn more about PSG, visit www.psgequity.com.